Why Many Oncologists Still Reach for G-CSF Over Trilaciclib in ES-SCLC

Febrile neutropenia remains one of the most consequential complications of frontline chemotherapy for extensive-stage small cell lung cancer (ES-SCLC), in part because the population most likely to develop it is also the population least equipped to tolerate it. Patients with ES-SCLC tend to be older, more heavily comorbid, and more likely to present acutely ill than other lung cancer populations, and a single early neutropenic event can complicate an already narrow treatment window.

In a virtual Case-Based Roundtable event for oncologists in the Chicago area, Julia Rotow, MD, clinical director of the Lowe Center for Thoracic Oncology and director of clinical research at Dana-Farber Cancer Institute, reviewed supportive care strategies for chemotherapy-induced neutropenia in patients receiving platinum/etoposide- or topotecan-based regimens for ES-SCLC. Rotow opened with a case of early, severe decompensation and used it to probe how closely participants' real-world granulocyte colony-stimulating factor (G-CSF) practices matched NCCN risk-based guidance and how willing they were to consider a newer multilineage-protective alternative.

The discussion centered on a 51-year-old woman with a 20-pack-year smoking history and a prior thyroidectomy for papillary thyroid carcinoma who presented with cough, chest pain, and dyspnea. Workup revealed a pleural-based lung mass with mediastinal lymphadenopathy, and biopsy confirmed small cell lung cancer; pleural and pericardial involvement placed her outside the radiation field, and she began carboplatin, etoposide, and atezolizumab (Tecentriq) for ES-SCLC. Two weeks after her first cycle, she developed febrile neutropenia with an absolute neutrophil count of 100 and sepsis in the setting of pneumonia.

That kind of early, acute decompensation set the tone for the discussion. Mohamad K. Khasawneh, MD, described patients who present "acutely sick" with bulky disease and postobstructive pneumonia, where chemotherapy often starts inpatient with chemotherapy alone because immunotherapy isn't yet feasible. Other participants agreed that performance status is hard to interpret in this population, since it's often unclear how much decline reflects the malignancy itself rather than true baseline frailty. Several oncologists nonetheless ranked myelosuppression below infection risk, renal dysfunction, and respiratory complications on their list of day-to-day concerns; cytopenias, one participant noted, are something oncologists already "deal with...all the time in other regimens."

Rotow cited a retrospective analysis of more than 3000 patients with ES-SCLC treated in the community setting showing that 45% experienced grade 3 or higher neutropenia, with roughly 1 in 5 patients hospitalized within the first 3 weeks of starting chemotherapy.¹ Despite that burden, only 61% of patients received long-acting granulocyte colony-stimulating factor (G-CSF) within 3 days of treatment initiation—a gap that matched what most participants described in their own practices. Most said they rarely use prophylactic G-CSF up front, reserving it instead for older patients or those with identifiable risk factors such as bulky disease, renal impairment, or prior neutropenic events. That approach lines up with NCCN guidance recommending primary G-CSF prophylaxis for regimens carrying a 20% or higher risk of febrile neutropenia, and consideration of prophylaxis for intermediate-risk regimens in patients with additional risk factors; low-risk regimens generally don't warrant routine prophylaxis.^2-4

Several participants said insurance coverage, not clinical judgment, often dictates timing. One oncologist noted that payers typically require documentation of an actual neutropenic event before approving G-CSF for a given regimen, making truly proactive, cycle 1 prophylaxis difficult to secure even in patients oncologists already suspect are high risk. Khasawneh said he leans on NCCN risk factors—advanced age, renal failure, bulky disease, extensive-stage disease itself—to build the case for early approval, but reserves G-CSF for patients who clearly meet that threshold rather than offering it universally.

The more striking gap concerned trilaciclib (Cosela), a CDK4/6 inhibitor that several participants said they understood poorly despite recognizing its rationale. Rotow explained that trilaciclib blocks CDK4/6-dependent cell cycle progression in hematopoietic stem and progenitor cells, transiently arresting healthy marrow cells while leaving CDK4/6-independent tumor cells—a hallmark of RB-mutated small cell lung cancer—fully exposed to chemotherapy cytotoxicity. In a pooled analysis of 3 randomized phase 2 studies—G1T28-02 (NCT02499770), G1T28-03 (NCT02514447), and G1T28-05 (NCT03041311)—enrolling patients with newly diagnosed or previously treated ES-SCLC, trilaciclib reduced rates of severe neutropenia and cut hospitalizations attributed to myelosuppression or sepsis to 4.1% vs 13.6% with placebo, without a significant difference in overall survival between arms.⁵

Even with that safety signal, skepticism ran through the room. Sangeetha Nimmagadda, MD, said insurance had declined coverage for a patient she felt was an appropriate candidate, with payers suggesting growth factor could be used "if needed"—reflecting a broader concern that trilaciclib hasn't been studied head-to-head against G-CSF. Nandini Kalakota, MD, said the evidence had initially seemed weak to her, particularly because most patients can't start the infusion before cycle 1 given logistical and insurance delays; by the time approval comes through, patients are often already past their most vulnerable early cycles. One oncologist pressed Rotow on why insurers should approve a meaningfully costlier agent without a randomized comparison to growth factor, a question Rotow acknowledged she couldn't fully answer but agreed was fair.

Khasawneh, who had used trilaciclib in a patient admitted with postobstructive pneumonia, offered the dissenting view: in a population this acutely ill, he said, "the data that supports the use of trilaciclib is actually pretty convincing," citing lower rates of neutropenic sepsis while chemotherapy intensity is preserved. That divide—between oncologists waiting for harder comparative evidence and those willing to act on directional benefit in a high-risk population—carried directly into the second case of the evening, where multilineage cytopenias, not neutropenia alone, took center stage.

REFERENCES

1. Epstein RS, Krenitsky J, Sangoi M, et al. Real-world incidence and clinical outcomes of chemotherapy-induced myelosuppression in patients treated with chemotherapy for extensive-stage small cell lung cancer. Adv Ther. 2020;37:3606-3618. doi:10.1007/s12325-020-01419-z

2. NCCN. Hematopoietic Growth Factors. Version 1.2025. Accessed June 24, 2026. https://www.nccn.org/guidelines/category_2

3. NCCN. Small Cell Lung Cancer. Version 4.2025. Accessed June 24, 2026. https://www.nccn.org/guidelines/category_1

4. NCCN. Prevention and Treatment of Cancer-Related Infections. Version 3.2024. Accessed June 24, 2026. https://www.nccn.org/guidelines/category_2

5. Weiss J, Goldschmidt J, Andric Z, et al. Effects of Trilaciclib on Chemotherapy-Induced Myelosuppression and Patient-Reported Outcomes in Patients with Extensive-Stage Small Cell Lung Cancer: Pooled Results from Three Phase II Randomized, Double-Blind, Placebo-Controlled Studies. Clin Lung Cancer. 2021 Sep;22(5):449-460. doi: 10.1016/j.cllc.2021.03.010. Epub 2021 Mar 26. PMID: 33895103.